IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new data from an ongoing study indicates the BluePrint® functional molecular subtyping assay more accurately identifies molecular subgroups and may be a better guide for neoadjuvant treatment than standard, local IHC/FISH assays.
Help employers find you! Check out all the jobs and post your resume.
